Hydrochlorothiazide Tablets using PEARLITOL® 50 C Mannitol, LYCATAB® DSH Maltodextrin and Maize Starch Extra White (Wet Granulation)
Published January 27, 2026
Resource
Pharma
Hydrochlorothiazide tablets produced via wet granulation containing PEARLITOL® 50 C Mannitol as filler and LYCATAB® DSH Maltodextrin as binder solution

Formula:
| | % (By weight) | mg / tablet |
|---|---|---|
| PEARLITOL® 50 C mannitol | 67.5 | 459.0 |
| Maize Starch Extra White | 17.5 | 119.0 |
| Hydrochlorothiazide | 10.0 | 68.0 |
| LYCATAB® DSH maltodextrin | 4.0 | 27.2 |
| Magnesium stearate | 1.0 | 6.8 |
Method:
- Mix all the ingredients except the binder and the lubricant in a planetary mixer for 5 minutes at low speed.
- Disperse the binder in water and add the solution (23.5%, w/w) to the powders and mix for 10 minutes.
- Pass the wet blend through the 1000 µm sieve of an oscillatory granulator.
- Dry the granules for 20 minutes at 60 oC in a fluidized bed dryer.
- Sieve the granules through a 1000 µm sieve.
- Lubricate with magnesium stearate in a mixer for 5 minutes.
- Compress using a single-punch press fitted with flat 11.25 mm diameter punches.
Additional comments:
- Target Tablet Properties
- Tablet hardness: 120 N
- Disintegration time: 490 s - PEARLITOL® mannitol is used as a filler and filler/binder as well as a bulk sweetener. The PEARLITOL® range offers a unique blend of exceptional physical and chemical stability and no hygroscopicity. With great organoleptic, non-cariogenic and sugar-free properties, PEARLITOL® is suitable to be used in formulations addressing various patient populations including pediatric and diabetic.
- LYCATAB® DSH maltodextrin is a high-performance wet granulation binder. It is completely soluble in cold water and has excellent wettability. These characteristics make it a versatile excipient for most granulation equipment and for binder incorporation (in the dry mix or as a binder solution).
Disclaimer:
This formula is a guideline for recommended use of our products; it does not imply consent to their use in violation of existing patent(s).
These details are for information only, and we believe them to be reliable.